Showing 1–14 of 14 documents
Sorted by hybrid relevance (keyword + semantic via RRF)
A.A. Danhausa, E.E. Daniel, C.J. Shawulu, Adamu Nuhu, L. Philemon
Regardless of many decades of research, the widespread availability of a vaccine and more recently highly visible WHO efforts to promote a unified global control strategy, Tuberculosis remains a leading cause of infectious mortality. In this paper, a Mathematical Model for Tuberc…
Robyn S. Lee, Jean‐François Proulx, Fiona McIntosh, Marcel A. Behr, William P. Hanage
… genomic data either alone or in conjunction with classical epidemiology to investigate TB transmission dynamics in the Canadian North, (Tyler et al., 2017; Lee et al., 2015a; Lee et al., 2015b) with the aim of identifying clusters to help guide public health interventions. Thus …
Conor J. Meehan
… genomic data either alone or in conjunction with classical epidemiology to investigate TB transmission dynamics in the Canadian North, (Tyler et al., 2017; Lee et al., 2015a; Lee et al., 2015b) with the aim of identifying clusters to help guide public health interventions. Thus …
Benjamin Idoko Omede, Olumuyiwa James Peter, William Atokolo, Bolarinwa Bolaji, Tawakalt Abosede Ayoola
The rise of drug resistance has become a major obstacle in treating tuberculosis (TB), significantly contributing to the increasing disease burden. Therefore, it is essential to study the transmission dynamics of the disease, considering the factors that contribute to the strain’…
Susanna S van Wyk, Marriott Nliwasa, F. Lu, Chih-Chan Lan, James A. Seddon, et al.
<sec> <title>BACKGROUND</title> Finding individuals with drug-resistant tuberculosis (DR-TB) is important to control the pandemic and improve patient clinical outcomes. To our knowledge, systematic reviews assessing the effectiveness, cost-effectiveness, acceptability, and feasib…
Ahmad Fuady
Estimating tuberculosis incidence, prevalence, and deaths are crucial to capture the tuberculosis burden and to assess the progress towards tuberculosis elimination in 2035. WHO publishes a report of estimated tuberculosis burden each year, showing that tuberculosis remains among…
Karen D. Serrano, Scott A. Fruhan
…ssociated with TB. This review details the pathophysiology, epidemiology, clinical presentation, and treatment of pulmonary infection, including pneumonia, empyema, pulmonary abscess, and tuberculosis (TB). Figures show chest radiographs of reactivation pulmonary tuberculosis, HI…
Karen D. Serrano, Scott A. Fruhan
…ssociated with TB. This review details the pathophysiology, epidemiology, clinical presentation, and treatment of pulmonary infection, including pneumonia, empyema, pulmonary abscess, and tuberculosis (TB). Figures show chest radiographs of reactivation pulmonary tuberculosis, HI…
V.B. Avdentova, E.M. Belilovsky, Borisov Se, E. M. Bogorodskaya, O. N. Zuban, et al.
Objective: to determine the association of various patient characteristics with unfavourable treatment outcomes of adult pulmonary tuberculosis (TB) without multidrug resistance in a region with low epidemiological rates. Methods. We studied treatment outcomes in 887 drug-suscept…
Debdeep Mitra, P. Sanyal, Divya Kamboj, Rakesh Kumar Deepak, Sayan Chakraborty, et al.
…erapy in DR-TB treatment may have significant impact on the epidemiology of disease transmission.
World Health Organization
This web annex to the WHO consolidated guidance on tuberculosis data generation and use provides practical examples illustrating how tuberculosis (TB) diagnosis, treatment initiation and treatment outcomes should be recorded and reported within TB surveillance systems. Using a se…
Otsuka Pharmaceutical Development & Commercialization, Inc.
This trial will assess the safety and efficacy of OPC-167832 combined with delamanid and bedaquiline in participants with drug-susceptible tuberculosis (DS-TB) administered for 17 weeks compared to rifampin, isoniazid, ethambutol, pyrazinamide (RHEZ) administered for 26 weeks. E…
Markus Soner
Tuberculosis is a major yet preventable airborne infectious disease. From the infectious diseases caused by a single pathogen, tuberculosis has caused the most deaths in the world per year until the COVID-19 pandemic. In 2019, an estimated 10 million new TB cases emerged, and mor…
Veronique R de Jager, MD, Prof. Rodney Dawson, MD, Prof. Andreas Diacon
This trial will evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of multiple oral doses of OPC-167832 in participants with uncomplicated, smear-positive, drug-susceptible pulmonary tuberculosis (TB).